D
evelopmental dysplasia of the hip (DDH) encompasses luxation, subluxation, instability, and an array of radiographic abnormalities that reflect inadequate formation of the acetabulum. 1 A number of risk factors have been associated with DDH including in utero neuromuscular fetal abnormalities, such as arthrogryposis and breech presentation, and acquired factors such as cradling and clothing with hips extended and adducted. A 5:1 female preponderance has been noted, while ligamentous laxity and maternal relaxin have also been implicated. 1, 2 Thyroid hormone plays a pivotal role in the normal development of bones and muscle. Abnormalities in infants born to mothers with Graves disease 3 indicate that maternal hyperthyroidism may predispose to an increased risk of DDH. Gestational transient hyperthyroidism is one of the 2 main causes of hyperthyroidism observed in the pregnant state and is associated with a direct stimulation of the maternal thyroid gland by human chorionic gonadotropin (hCG). 4, 5 As elevated hCG levels are also associated with hyperemesis, not surprisingly hyperthyroidism is a common, self-limited finding in severe hyperemesis gravidarum with an incidence of up to 73%. 6 Thus, this latter condition could be used as an indirect marker for the risk of transient hyperthyroidism.
We hypothesized that maternal hyperthyroidism in the first trimester manifesting either as Graves disease or as gestational transient hyperthyroidism was a risk factor in the later development of DDH.
METHODS
A retrospective review of all infants born in YukiguniYamato General Hospital from 1996 to 2003 was conducted; 2137 children were born during this period. They were examined for DDH by experienced pediatricians during regular health examination visits at 1 day, 1 week, 1 month, and 4 months after birth. If an infant showed signs of DDH (Ortolani and Barlow maneuvers and limited abduction), an orthopaedic specialist was consulted at 4 months of age, and the diagnosis was made by physical examination and anteroposterior pelvis radiographs. The final diagnosis of DDH was given after subsequent follow-up in which absence of natural improvement was confirmed. To exclude the influence of acquired risk factors of DDH, we studied only neonatal DDH (n-DDH) and defined n-DDH as infants who showed signs of DDH before they were 1 month old.
In infants born to mothers with Graves disease, thyroid function was measured in infants at an early neonatal period (free T 3 [FT 3 ], free T 4 [FT 4 ], thyroid-stimulating hormone [TSH], autoantibody to TSH receptor, thyroid microsome antibody, thyroglobulin antibody, and bone age).
In all infants born to mothers without Graves disease, their mother_s antenatal history was checked for hyperemesis in the first trimester requiring hospitalization and intravenous fluid management due to irresistible vomiting for several weeks. This group was defined as having severe hyperemesis gravidarum. The association between this cohort and n-DDH cases was also analyzed. In this study, antithyroid drugs were not given for the group. Bone ages were evaluated by the method of Roche et al. 7 performed using the W 2 test. A P G 0.05 was considered significant.
RESULTS
In the 2083 infants whose mothers did not have either severe hyperemesis gravidarum or Graves disease, 13 were diagnosed with n-DDH (0.63%; Table 1 ). Fifteen infants were born to mothers with Graves disease, and 3 of these infants (20%, P G 0.0001) were diagnosed with n-DDH. Of the 39 women diagnosed with severe hyperemesis gravidarum in the first trimester, 5 had infants diagnosed with n-DDH (12.8%, P G 0.0001).
In total, 21 n-DDH cases were diagnosed in this cohort. Other than female sex (P G 0.05), no other antenatal or postnatal factors were found to be associated with the diagnosis of n-DDH including presentation at delivery, mode of delivery, birth weight, or gestational age (Table 2 ). There was no history of parental consanguinity or multiple pregnancy in any of the affected infants, and no infant was born with neuromuscular conditions associated with n-DDH. All 21 n-DDH cases were treated with Pavlik harness and succeeded in correction.
Of the 7 affected children delivered to women with either Graves disease or hyperemesis gravidarum, 6 had cephalic presentations and vaginal deliveries (1 was breach at cesarian section). All 7 children were female.
Neonatal thyroid function in the 3 affected infants of Graves mothers demonstrated transient and mild elevations in FT 4 in 2 of the subjects (G-2, G-3) on days 1 and 3 (36.0 and 42.3 pmol/L, respectively) with TSH levels of 17 K/mL on both occasions. These values returned to normal without intervention. In subsequent follow-up examinations, no thyroid dysfunction was noted. The other 12 infants born to mothers with Graves disease demonstrated normal thyroid function. In all these 15 infants, bone age was normal.
DISCUSSION
Our data indicate that mothers with thyrotoxicosis, either clinically proven as in Graves disease or indirectly with the diagnosis of hyperemesis gravidarum, should be considered as a high-risk group for the development of n-DDH. The method of screening used in this study was almost identical to the guidelines of the Committee on Quality Improvement and Subcommittee on Developmental Dysplasia of the Hip. 1,2 All infants were screened and diagnosed without using ultrasonography, and the total incidence of n-DDH in this study was the same as the Japanese general prevalence of DDH (0.3%Y0.7%) that was screened by physical examination. Thus, the incidence of n-DDH in infants born to mothers with Graves disease and of infants born to mothers with severe hyperemesis in the first trimester of pregnancy was increased 10 to 30 times the normal.
Thyroid hormone_s role in bone maturation and muscle development indicates why abnormalities in maternal thyroid hormone homeostasis during embryogenesis may result in DDH. 8, 9 Embryologically, the femoral head and acetabulum develop from the same block of primitive mesenchymal cells. A cleft develops to separate them at 7 to 8 weeks of gestation, and by 11 weeks, the development of the hip joint is complete. 1 The TSH receptor is not expressed in human fetuses before 10 to 12 weeks_ gestation, indicating that the fetal hypothalamicpituitary-thyroid axis is not functional during this period of embryogenesis. 10 However, maternal thyroid hormone can be demonstrated in the embryonic coelomic cavity as early as 6 weeks_ gestation and is considered to play an important role in early fetal development.
11Y13 Furthermore, placental metabolism of thyroxine and triiodothyronine prevents fetal tissues being exposed to higher maternal levels that may prove harmful. 12, 13 Thus, it is likely that excessive levels of thyroid hormone from the mother before 12 weeks_ gestation might result in increased embryonic thyroxine and triiodothyronine levels and subsequently affect the formation of the fetal hip joint, and thereby the development of n-DDH.
Gestational transient hyperthyroidism is associated with a direct stimulation of the maternal thyroid gland by hCG and is 1 of the 2 main causes of hyperthyroidism observed in the pregnant state. 4, 5 Hyperthyroidism is a common, self-limited finding in hyperemesis gravidarum occurring up to 73%. 6 As this was a retrospective study, we had no data on thyroid function in those subjects who have hyperemesis gravidarum. However, in view of the strong association between these 2 conditions, we believe it is a reasonable, indirect marker of transient hyperthyroidism.
Female infants are known to have an increased risk of DDH. 1, 2 In our cohort, 18 of the 21 infants were female, and all 7 of those were affected with either maternal hyperemesis gravidarum or Graves disease. It is possible that this sex difference reflects the ability to convert thyroxine to the more biologically active triiodothyronine in fetal life. Following observations of sex dimorphism in the epiphysial development of newborns with congenital hypothyroidism, it was proposed that less efficient conversion of thyroxine to triiodothyronine occurs in the male fetus. 9 Consequently, the male fetus may be relatively protected from elevations in maternal thyroxine, whereas the female fetus may be at greater risk.
This study is limited by its relatively small size. However, our findings are consistent across 2 populations of mothers; one with first trimester Graves disease and another at risk of transient first trimester hyperthyroidism. Although further studies are required to confirm these findings, they have a biologically plausible explanation and indeed may explain the female predominance observed in this condition.
In conclusion, n-DDH was observed more frequently in infants born to mothers with both Graves disease and hyperemesis gravidarum. We speculate this is a consequence of elevated triiodothyronine levels in the first trimester and that a female predominance is observed because of enhanced conversion of triiodothyronine from thyroxine. Infants of mothers with these conditions should be carefully assessed in the neonatal period for signs of n-DDH.
